This is a preview of subscription content, log in via an institution to check access.
Notes
Three drugs were excluded from the anaylsis: the two most recently approved drugs, peginterferon-β-1a [Plegridy] and alemtuzumab [Lemtrada] because costs data were unavailbale, and generic mitoxantrone because it is infrequently used due to safety concerns.
References
Hartung DM, et al. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry. Too big to fail? Neurology : 24 Apr 2015. Available from: URL: http://dx.doi.org/10.1212/WNL.0000000000001608
Murray TJ, et al. Escalating MS drug costs in the US: Puzzling, troubling, and suspicious. Neurology : 24 Apr 2015. Available from: URL: http://dx.doi.org/10.1212/WNL.0000000000001624
Rights and permissions
About this article
Cite this article
"Alarming rise" in MS drug costs in the US over last 20 years. PharmacoEcon Outcomes News 727, 6 (2015). https://doi.org/10.1007/s40274-015-2090-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2090-1